Blocking the signal: Brain-derived growth factor may lure lung cancer cells to migrate

August 13, 2014 by Nancy Fliesler
Blocking the signal: Brain-derived growth factor may lure lung cancer cells to migrate
Researchers have found a molecule that may influence metastasis in adenocarcinoma, the most common type of lung cancer. Credit: Eraxion/iStock

(Medical Xpress)—Ninety percent of lung cancer deaths are caused by the tumor's spread—or metastasis—to other organs. Researchers have now discovered an approach to blocking metastasis in the most common type of lung cancer, adenocarcinoma, that could be added to chemotherapy treatments aimed at shrinking the primary tumor.

Kerstin Sinkevicius, a research fellow at Boston Children's Hospital, started with this question: Is there anything in a lung tumor's environment that makes it metastasize? She sampled tissue from human lymph nodes—the first place cancers typically spread to—to see if the cells there were secreting anything that might lure cancer cells to migrate.

One chemical stood out: a growth factor called brain-derived neurotrophic factor, or BDNF. Secreted near maturing neurons, BDNF is best known for its role in stimulating the developing nervous system.

A brain factor? Yes. When Sinkevicius took BDNF out of the equation, migration of adenocarcinoma cells in culture dropped nearly twofold, suggesting that the cancer cells take advantage of the same signals neurons use.

"A lot of times cancer cells use mechanisms that are built in," explained Sinkevicius.

She and senior investigator Carla Kim, Harvard Medical School associate professor of genetics at Boston Children's, then systematically looked for anything in the primary that might be drawn by BDNF's signal. Could blocking that communication prevent from migrating?

That question led them to a cellular receptor molecule called TrkB. When the researchers took that out of the equation, cell migration was again significantly decreased. And when they deleted TrkB in a live mouse model of adenocarcinoma, only 17 percent of the mice got metastases, as compared with the usual rate of 50 percent.

"The primary tumors were the same, so we think TrkB is specifically important for metastasis," said Sinkevicius. Their findings were published in July in the Proceedings of the National Academy of Sciences.

When adenocarcinoma cells were cultured in low-oxygen conditions—conditions under which lung cancers are more apt to metastasize—TrkB was especially abundant. "Oxygen-deprived tumor cells are stressed out and may be looking to go somewhere else," said Sinkevicius. And TrkB is their ticket.

A two-pronged strategy for lung cancer?

Traditionally, metastasis has been an understudied area in cancer. Companies generally prefer to seek out agents that shrink the primary tumor—a metric that's fairly short term and easily measurable. Antimetastatic agents are a less attractive investment, since metastasis is variable and can take years to occur.

However, compared with previously identified targets for preventing metastasis, TrkB may be easier to hit, said Kim, since chemical TrkB inhibitors are already available and being tested for depression and neurologic disorders such as epilepsy.

"There may be patients for whom TrkB inhibition is particularly useful," she said. "Certain subsets of have higher levels of TrkB."

In their study, she and Sinkevicius found that targeting TrkB was especially effective in the roughly 60 percent of adenocarcinomas that lack two commonly seen mutations, in the genes Kras and EGFR.

And other metastasis-inhibiting compounds could emerge from this work. Kim hopes to do gene-expression studies to see if there are changes in gene activity when TrkB is inhibited. These could help find additional drug targets.

"This is just one hit from the screen Kerstin did," she said. "It demonstrates that you can use a simple cell line-based screen to identify important molecules in metastatic ."

Explore further: Cancer researchers identify new metastasis suppressor gene

More information: PNAS paper -

Related Stories

Cancer researchers identify new metastasis suppressor gene

July 14, 2014
(Medical Xpress)—Among patients with deadly cancers, more than 90 percent die because of metastatic spread of their disease. Looking to target a key pathway in order to interfere with the processes that lead to tumor spread, ...

Stopping the spread of breast cancer

June 3, 2014
The primary cause of death from breast cancer is the spread of tumor cells from the breast to other organs in the body. Northwestern Medicine® scientists have discovered a new pathway that can stop breast cancer cells from ...

Regulator of gene expression responsible for the progression of breast cancer

February 28, 2014
Yale Cancer Center researchers have identified a regulator of gene expression that is responsible for the progression of breast cancer and its metastasis to the lung. The study appears online in Cell Reports.

Cell mechanics may hold key to how cancer spreads and recurs

August 7, 2014
(Medical Xpress)—Cancer cells that break away from tumors to go looking for a new home may prefer to settle into a soft bed, according to new findings from researchers at the University of Illinois.

Researchers identify a treatment that prevents tumor metastasis

July 24, 2014
Metastasis, the strategy adopted by tumor cells to transform into an aggressive form of cancer, are often associated with a gloomy prognosis. Managing to block the metastasis or, even better, prevent their formation would ...

Move over Prozac: New drug offers hope for depression

April 18, 2011
The brain chemistry that underlies depression is incompletely understood, but research suggests that aberrant signaling by a chemical called Brain-Derived Neurotrophic Factor through its receptor TrkB, may contribute to anxiety ...

Recommended for you

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.